Core Viewpoint - Eight A-share listed companies have failed to disclose their annual reports on time, with some actively pursuing delisting, while others face verification issues [1][2][3]. Group 1: Companies with Delayed Annual Reports - The eight companies include Yulong Co., AVIC Industry Finance, Puli Tui, ST Xinchao, Zitian Technology, Jinlitai, Tianmao Group, and *ST Hengli [2][3]. - Among these, Yulong Co., ST Xinchao, AVIC Industry Finance, and Tianmao Group have market capitalizations exceeding 10 billion yuan, with AVIC Industry Finance reaching 30.6 billion yuan [2]. - The remaining four companies have significantly lower valuations, with Jinlitai around 2 billion yuan and the others below 2 billion yuan [2]. Group 2: Reasons for Delayed Reports - Yulong Co. and AVIC Industry Finance are actively pursuing delisting, which prevents them from timely disclosing their 2024 annual reports [3]. - Puli Tui has received a decision from the Shenzhen Stock Exchange regarding the termination of its stock and convertible bonds [3]. - Jinlitai's delay is due to incomplete verification of financial information, while Tianmao Group and ST Xinchao require further information verification [3]. - *ST Hengli cited the need for additional information and delays from the auditing firm as reasons for its report delay [3]. - Zitian Technology failed to complete its audit due to not hiring an annual audit accountant [3]. Group 3: Stock Performance Amid Report Delays - Despite the report delays, ST Xinchao's stock price increased by 38.36% in April, possibly due to competitive takeover offers [4][5]. - In contrast, Tianmao Group and *ST Hengli experienced stock price declines after announcing their report delays, with Tianmao Group's stock hitting the limit down for two consecutive days [4][5]. - The overall market reaction indicates a divergence in investor sentiment, with some companies facing significant operational risks due to their inability to disclose reports on time [5].

Group 1: Corporate Investigations and Issues - China Copper Industry Co., Ltd. director Li Lianbing is under investigation for serious violations of discipline and law [3] - Yong'an Pharmaceutical's actual controller and chairman Chen Yong is under investigation and has been detained [6] - Xianju Pharmaceutical received an administrative penalty of 195 million yuan for price-fixing agreements with competitors [10] Group 2: Corporate Transactions and Financial Warnings - AVIC Capital plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Avionics to its controlling shareholder for 4.067 billion yuan [7] - Jiangsu Wuzhong's stock will be subject to additional risk warnings due to an audit report with no opinion and non-operational fund occupation by related parties [8] - Tianmao Group and Jinlitai are both unable to disclose their periodic reports on time, leading to stock suspensions [10][11] Group 3: Industry Trends and Changes - Several automotive companies, including Li Auto, Xiaomi, NIO, and Xpeng, are shifting their marketing language from "smart driving" to "assisted driving" [21]

Mergers and Acquisitions - Xingye Yinxin plans to acquire Atlantic Tin Company for approximately 4.54 billion RMB, with a total investment of about 0.98 million AUD at a price of 0.24 AUD per share [1] - Electric Power Investment Energy is undergoing an asset restructuring with its actual controller, State Power Investment Corporation, involving the acquisition of Inner Mongolia Baiyin Hua Coal Power equity [2] - Huibo Yuntong intends to purchase control of Baode Computer System Co., Ltd. through a combination of share issuance and cash payment, with details to be disclosed in a restructuring report [3] Share Buybacks and Increases - Kesi Technology plans to repurchase shares worth between 30 million and 50 million RMB, using self-owned funds for employee stock ownership plans or capital reduction [4] - Fuchuang Precision's major shareholder, Shenyang Advanced Manufacturing Technology Industry Co., Ltd., aims to increase its stake in the company by 1.2 billion to 2.4 billion RMB over the next 12 months [5] Regulatory and Compliance Issues - Yong'an Pharmaceutical's actual controller and chairman, Chen Yong, is under investigation and has been detained, with the company monitoring the situation closely [6] - *ST Gongzhi received a notice of termination of listing due to financial reporting issues, including an audit report with no opinion expressed for the 2024 fiscal year [8] - Xianju Pharmaceutical was fined 195 million RMB for engaging in monopolistic practices related to the pricing of dexamethasone phosphate sodium raw materials [9] - *ST Hengli failed to disclose periodic reports within the legal timeframe, leading to potential termination of its stock listing [10] - Tianmao Group also failed to disclose its periodic reports on time, resulting in stock suspension [11]

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-42 恒立实业发展集团股份有限公司 关于无法在法定期限内披露定期报告致股票可能被终止上市暨 停牌的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： ●恒立实业发展集团股份有限公司（以下简称"公司"）因无法在法定期 限内（2025年4月30日）披露2024年年度报告及2025年第一季度报告，根据《深 圳证券交易所股票上市规则》（以下简称"股票上市规则"）的相关规定，公司 股票将于2025年5月6日（星期二）开市起停牌。 ●公司因无法在法定期限内披露2024年年度报告，根据《股票上市规则》 第9.3.12条（七）项"未在法定期限内披露过半数董事保证真实、准确、完整 的年度报告"，公司股票将被深圳证券交易所终止上市。敬请广大投资者谨慎 决策，注意防范风险。 根据《股票上市规则》第9.3.13条，公司股票自2025年5月6日（星期二）开 市起停牌。 根据《股票上市规则》第9.3.14条、第9.3.15条，深圳证券交易所自公司股 票停牌之日起五个交易日内，向公司发出拟终止公司股票 ...

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-41 恒立实业发展集团股份有限公司 一、无法在法定期限内披露报告的原因 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 关于无法在预约日期及预计无法在法定期限内披露定期报告的 深圳旭泰会计师事务所（普通合伙）（以下简称："旭泰会所"）对公司 2024 年年度报告审计过程中，未按照双方签订的《审计业务约定书》及《总体 审计策略》规定的时间、流程以及法定程序开展审计工作，公司于 2025 年 4 月 29 日下午 3 点后才收到旭泰会所出具的正式审计报告及其他相关专项报告。 风险提示公告 特别提示： ●恒立实业发展集团股份有限公司（以下简称"公司"）原定于2025年4月 30日披露2024年年度报告和2025年第一季度报告。因定期报告涉及的部分信息需 要进一步补充提供，公司无法在2025年4月30日披露2024年年度报告和2025年第 一季度报告，也可能无法在法定期限内（2025年4月30日）披露上述定期报告。 ●公司因无法在法定期限内披露 2024 年年度报告和 2025 年第一季度报告， 根据 ...

5. 玉龙股份（601028）：公司拟以股东大会决议方式主动撤回 A 股股票在上交所的上市交易，申请进 入全国中小企业股份转让系统退市板块继续交易，上交所已受理公司关于股票主动终止上市的申请。 6. 中航产融（600705）：公司拟以股东大会决议方式主动撤回 A 股股票在上交所的上市交易，转而申 请在全国中小企业股份转让系统转让，已向上交所提交终止上市申请，目前尚待上交所决定是否受理。 3. *ST恒立（000622）：公司股票连续三个交易日收盘价格跌幅偏离值累计达到 12％以上，存在 2024 年营业收入低于 3 亿元及财务会计报告和内部控制报告存在被出具非标准审计意见的风险，可能导致公 司股票 2024 年年度报告披露后被终止上市。 4. *ST九有（600462）：因 2023 年度经审计的期末归属于上市公司股东的净资产为负值，公司股票被 实施退市风险警示，若 2024 年度仍存在不符合申请撤销退市风险警示的情形，股票将面临被终止上市 的风险，同时公司还面临重大违法退市风险。 1. *ST东方（600811）：公司股票将于 2025 年 4 月 30 日终止上市暨摘牌，不进入退市整理期，终止上 市后将转 ...

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-40 恒立实业发展集团股份有限公司 关于公司股票交易异常波动及公司股票可能被终止上市的 风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要风险提示 ●恒立实业发展集团股份有限公司（以下简称"本公司"、"公司"或"恒 立实业"，证券简称：*ST恒立，证券代码：000622）股票连续三个交易日（2025 年4月24日、4月25日、4月28日）收盘价格跌幅偏离值累计达到12％以上，根据 《深圳证券交易所交易规则》的有关规定，公司股票交易属于异常波动情形。 ●公司存在2024年营业收入低于3亿元而被终止上市的风险，公司2024年度 财务会计报告和内部控制报告存在被出具非标准审计意见的风险，公司股票存 在2024年年度报告披露后被终止上市的风险。截至本公告日，公司已多次披露 《关于公司股票可能被终止上市的风险提示公告》，具体详见公司已披露的相 关公告（公告编号：2025-05、2025-07、2025-15、2025-27、2025-33、2025-38、 2025-39）。敬请广大投资 ...

Group 1 - Several listed companies, including *ST Hengli and Aucma, have postponed the disclosure of their 2024 annual reports and 2025 Q1 reports due to delays in audit and preparation work [1] - *ST Hengli has announced a delay in its report disclosure from April 28, 2025, to April 30, 2025, while Aucma's disclosure has been postponed from April 26, 2025, to April 30, 2025 [1] - Both companies have indicated potential risks, with *ST Hengli facing a possible delisting if its 2024 revenue falls below 300 million yuan, and Aucma correcting its previous profit forecast from a profit to a loss of 45 million to 50 million yuan [1][2] Group 2 - *ST Hengli's performance forecast indicates a revenue of 300 million to 350 million yuan for 2024, with total losses expected to be between 35 million and 45 million yuan [2] - The company has highlighted significant discrepancies with its auditors regarding revenue recognition, which could impact its final revenue figures [3] - Additionally, *ST Hengli is facing multiple lawsuits, resulting in the freezing of some bank accounts, which has negatively affected its operational activities [4] Group 3 - Aucma has unexpectedly revised its profit forecast, now expecting a loss of 45 million to 50 million yuan for 2024, with a further loss of 72 million to 78 million yuan when excluding non-recurring items [5] - The revision is attributed to incomplete audit assessments during the initial forecast, leading to the identification of impairment risks and the need for credit impairment provisions [5] - Aucma's declining performance is linked to insufficient domestic consumer demand and increased competition, alongside challenges faced by its new overseas investments [6]

智通财经4月23日电，*ST恒立(000622.SZ)公告称，由于公司与审计机构就一些重要事项仍在沟通确 认，是否导致年审会计师发表非标准审计意见存在不确定性，且审计工作尚未全部完成，公司将《2024 年年度报告》和《2025年第一季度报告》披露日期延期至2025年4月30日。公司预计2024年度扣除非经 常性损益后的净利润为-4,300万元至-3,300万元，扣除后营业收入为30,000万元至35,000万元。公司存在 2024年营业收入低于3亿元而被终止上市的风险。此外，公司股票自2024年5月6日起被深圳证券交易所 叠加实施退市风险警示及其他风险警示。 *ST恒立：延期披露2024年年度报告和2025年第一季度报告 存在终止上市风险 ...

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-39 恒立实业发展集团股份有限公司 关于延期披露 2024 年年度报告和 2025 年第一季度报告暨 公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要风险提示 ●截至本公告披露日，恒立实业发展集团股份有限公司（以下简称"公司"） 《2024 年年度报告》和《2025 年第一季度报告》的编制工作仍在开展，为确保 公司信息披露的准确性与完整性，基于谨慎性考虑，公司将《2024 年年度报告》 和《2025 年第一季度报告》披露日期延期至 2025 年 4 月 30 日。 ●公司披露了《2024年度业绩预告》（公告编号：2025-04）《关于2024年年 度报告编制及最新审计进展情况的公告》（公告编号：2025-32、2025-36），预 计2024年度扣除非经常性损益后的净利润为-4,300万元至-3,300万元，扣除后 营业收入为30,000万元至35,000万元。截至本公告日，《2024年年度报告》和 《2025年第一季度报告》编制工作仍在进行,审计工作 ...